Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + ftorafur + tamoxifen
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Hormonal Peptides → Native Peptides → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This drug combination consists of four components: 1. **Cyclophosphamide**: An alkylating agent that works by interfering with DNA replication and RNA transcription. 2. **Doxorubicin**: An anthracycline antibiotic that intercalates between DNA base pairs and inhibits topoisomerase II. 3. **Ftorafur (Tegafur)**: A prodrug of 5-fluorouracil (5-FU), which is a pyrimidine analog that inhibits thymidylate synthase and disrupts RNA function. 4. **Tamoxifen**: A selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors. This combination has been studied primarily for advanced and recurrent breast cancer, with clinical trials showing response rates of approximately 58% in some studies[2][3]. The regimen was designed to provide high antitumor effect with relatively manageable adverse reactions.
- Other names
- cyclophosphamide + doxorubicin + tegafur + tamoxifen
02
Targets
DNAESR1 (ERα)ESR2 (ERβ)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + ftorafur + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + ftorafur + tamoxifen.